鼻咽癌 (NPC) 在40至59岁男性中较为常见，放疗是一种有效的治疗方法。鼻咽淋巴瘤 (NPL) 是一种罕见的疾病，而鼻咽淋巴滤泡细胞淋巴瘤 (MCL) 与NPC的共存更是异常罕见的。碰撞肿瘤是一种罕见的肿瘤类型，指的是不同的两个或多个肿瘤同时发生在同一器官中。目前尚无报道描述在同一鼻咽肿块中同时发生NPC和MCL的碰撞肿瘤。我们在此报告了一例独特的NPC和MCL同时存在于一名中国男性鼻咽部的病例的成功治疗。一名58岁男性患者出现了5个月的吞咽不适史。在鼻咽内窥镜下进行了活检，组织病理学显示出NPC。磁共振成像显示鼻咽、口咽、扁桃体有病变，以及腮腺、耳后和颈部淋巴结肿大。这可能是一种伴有NPC和NPL共存的同步双原发肿瘤。病理会诊确认了鼻咽活检标本是NPC和MCL的碰撞肿瘤。正电子发射计算机断层扫描（PET-CT）显示鼻咽后壁增厚，考虑为伴有淋巴瘤的NPC。咽淋巴环增大和多发代谢亢进淋巴结被评估为淋巴瘤浸润。患者接受了两个周期的R-CHOP化疗（利妥昔单抗、环磷酰胺、多柔比星、长春碱和泼尼松）后进行头颈部放疗。截至写作本文的时候，他自初始治疗以来已经存活了61个月，并且仍在进行随访。正确识别碰撞肿瘤是非常重要的。磁共振成像有助于识别碰撞肿瘤的不同成分。病理检查有助于确认诊断。组织学检查揭示了不同的成分，PET-CT可以帮助确定病变的程度。剂量调整化疗联合放疗可能具有良好的治疗效果，但需要进一步的病例研究予以确认。© 2023. BioMed Central Ltd., part of Springer Nature.

Nasopharyngeal carcinoma (NPC) is more common in men aged 40 to 59, and radiotherapy is an effective treatment. Nasopharyngeal lymphoma (NPL) is rare, and the coexistence of nasopharyngeal mantle cell lymphoma (MCL) and NPC is even rarer. A collision tumor is a rare type of tumor that refers to two or more different tumors occurring in the same organ. No reports to date have described a collision tumor of NPC and MCL occurring within the same nasopharyngeal mass. We herein report the successful treatment of a unique case of synchronous coexistence of NPC and MCL occurring in the nasopharynx of a Chinese man.A 58-year-old man presented with a 5-month history of swallowing discomfort. Biopsy was performed under nasopharyngeal endoscopy, and histopathology revealed NPC. Magnetic resonance imaging revealed lesions in the nasopharynx, oropharynx, and tonsils, as well as enlarged lymph nodes in the parotid gland, posterior ear, and neck. This may be a synchronous dual primary tumor coexisting with NPC and NPL. Pathology consultation confirmed that the biopsy specimen of the nasopharynx was a collision tumor of NPC and MCL. Positron emission tomography computed tomography (PET-CT) revealed thickening of the posterior wall of the nasopharynx, which was considered NPC with lymphoma. The enlargement of the pharyngeal lymph ring and multiple hypermetabolic lymph nodes were evaluated as lymphoma infiltration. The patient received two courses of R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by head and neck radiotherapy. At the time of this writing, he had remained alive without recurrence for 61 months since the initial treatment and was still undergoing follow-up.It is very important to correctly recognize collision tumors. Magnetic resonance imaging helps identify different components of collision tumors. Pathological examination helps to confirm the diagnosis. Histological examination reveals different components, and PET-CT can help determine the extent of the lesion. Dose-adjusted chemotherapy combined with radiotherapy may have promising herapeutic effects, but additional case studies are needed to confirm.© 2023. BioMed Central Ltd., part of Springer Nature.